Navigation Links
Signalife Establishes Signalcare Division
Date:2/14/2008

LOS ANGELES, Feb. 14 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has established a division focused on developing, acquiring and/or testing therapies capable of treating cardiovascular disease at an earlier state and in a more effective manner.

From experience gained and relationships developed through the deployment of its award-winning Fidelity 100 Heart Monitor - including extensive utilization of the Fidelity 100 at this year's Super Bowl in Glendale, Arizona -- the Company has already learned significant details regarding the relationship between earlier and more accurate cardiovascular monitoring, on the one hand, and effective cardiovascular treatment-oriented technologies, on the other hand.

Dr. Lowell Harmison, the Company's President and Chief Executive Officer, commented that "more effective heart monitoring can be used to validate or invalidate technologies that, before now, were unable to be properly vetted. Through the use of our suite of heart monitoring devices and technologies, we believe that it is time to assist in moving the treatment of cardiovascular disease to earlier, less invasive and more predictable methodologies."

The Company has divisionalized Signalcare for the time being, and will evaluate placing Signalcare into a wholly-owned subsidiary after developments and relationships have materialized or have become formalized.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Signalife to Deploy Fidelity 100 Heart Monitors for AFL
2. LifeNet Health Establishes The Skin & Wound Allograft Institute
3. Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology
4. AT&T Establishes New Network Services for Leading Medical Liability Insurer
5. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
6. Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service
7. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
8. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
9. CIG Corp. Establishes a Medical Advisory Board
10. MM2 Group Establishes New Venture for Sofgel Manufacture in China
11. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... ... of Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly ... management information has been condensed to a single page, maximizing usability and improving ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video can get a jump ... winner will earn a $1,000 scholarship and have his or her video posted on ... deadline is May 31, with the winner announced on June 9. , The competition ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics announced this week ... Tranquility privacy panel system was designed to deliver the ideal blend of acoustic ... and provide the visual privacy required to maintain concentration levels and increase productivity. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Allegheny Health Network ... patients who seek access to the Network’s programs and services in the greater Pittsburgh ... specialty care appointments will be offered one for that same afternoon. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady Insurance Agency, a ... throughout eastern Georgia, is embarking on a charity effort to raise awareness and ... Americans every year than anything else, yet risk factors associated with heart disease ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... ViewRay, Inc. (Nasdaq: VRAY) announced today that the ... in Germany , has purchased a ... University Clinic Heidelberg as part of its initiative for ... will be headed by Medical Director and Professor Jürgen ... the German Cancer Research Center (DKFZ), the Heidelberg Heavy ...
(Date:1/19/2017)... , January 19, 2017 ... appears serious about reducing the FDA,s regulatory strictness ... in the medical drug industry, many of the ... new clinical trials and development of advanced drug ... ahead with recent developments include:  Moleculin Biotech, Inc., ...
(Date:1/19/2017)... ALAMEDA, Calif. , Jan. 18, 2017 /PRNewswire/ ... (MPI) solutions has entered into an agreement with ... for the Momentum MPI imaging system based on ... VivoQuant will be distributed as a complete MPI ... to enable quantitative nanoparticle or cell imaging in ...
Breaking Medicine Technology: